

Navigating the Treatment of Schizophrenia Using LAIs in the Time of COVID-19—Bibliography

- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. December 2019 draft. APA website. <https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines>. Accessed July 2020.
- America's Biopharmaceutical Companies. Medicines in development, 2019 report: mental illness. PhRMA website. <https://www.phrma.org/en/Report/Medicines-in-Development-for-Mental-Illness-2019-Report>. Accessed July 2020.
- Anglin DM, Galea S, Bachman P. Going upstream to advance psychosis prevention and improve public health [published online ahead of print, April 1, 2020]. *JAMA Psychiatry*. 2020.
- Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2011;25(5):567–620.
- Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(8):830–839.
- Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. *Br J Psychiatry Suppl*. 1998;172(33):53–59.
- Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Ther Adv Psychopharmacol*. 2014;4(5):198–219.
- Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet*. 2020;395(10227):912–920.
- Brown E, Gray R, Lo Monaco S, et al. The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research. *Schizophr Res*. 2020;S0920-9964(20)30257-7.
- Carpenter WT Jr, Davis JM. Another view of the history of antipsychotic drug discovery and development. *Mol Psychiatry*. 2012;17(12):1168–1173.
- Chan SM, Chiu FK, Lam CW, Leung PY, Conwell Y. Elderly suicide and the 2003 SARS epidemic in Hong Kong. *Int J Geriatr Psychiatry*. 2006;21(2):113–118.
- Choi EPH, Hui BPH, Wan EYF. Depression and anxiety in Hong Kong during COVID-19. *Int J Environ Res Public Health*. 2020;17(10):3740.
- Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. *Expert Rev Clin Pharmacol*. 2016;9(2):169–186.
- Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. *Expert Rev Neurother*. 2017;17(10):1029–1043.
- Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. *Expert Rev Neurother*. 2013;13(7):767–783.
- Citrome L. Paliperidone palmitate—review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. *Int J Clin Pract*. 2010;64(2):216–239.
- Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. *Patient Prefer Adherence*. 2009;3:345–355.
- Citrome L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERIS™) for the treatment of schizophrenia. *Clin Schizophr Relat Psychoses*. 2018;12(3):130–141.
- Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. *J Clin Psychiatry*. 2016;77(6):764–771.
- Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. *J Clin Psychiatry*. 2016;77(suppl 3):1–24.

- Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. *World Psychiatry*. 2018;17(2):149–160.
- COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Updated July 16, 2020. <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Accessed July 2020.
- Dufort A, Zipursky RB. Understanding and managing treatment adherence in schizophrenia. Published online ahead of print, January 3, 2019.
- Ehret MJ, Davis E, Luttrell SE, Clark C. Aripiprazole lauroxil nanocrystal dispersion technology (Aristada Initio®). *Clin Schizophr Relat Psychoses*. 2018;12(2):92–96.
- Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. *J Clin Psychiatry*. 2015;76(3):253–262.
- Gannon JM, Conlogue J, Sherwood R, et al. Long-acting injectable antipsychotic medications: ensuring care continuity during the COVID-19 pandemic restrictions. *Schizophr Res*. 2020;S0920-9964(20)30253-X.
- Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry*. 2016;50(5):410–472.
- Gao J, Zheng P, Jia Y, et al. Mental health problems and social media exposure during COVID-19 outbreak. *PLoS One*. 2020;15(4):e0231924.
- Gardner KN, Nasrallah HA. Managing first-episode psychosis: rationale and evidence for nonstandard first-line treatments for schizophrenia. *Curr Psychiatry*. 2015;14(7):33–45.
- Guo J, Feng XL, Wang XH, van IJendoorn MH. Coping with COVID-19: exposure to COVID-19 and negative impact on livelihood predict elevated mental health problems in Chinese adults. *Int J Environ Res Public Health*. 2020;17(11):3857.
- Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. *Patient Relat Outcome Meas*. 2014;5:43–62.
- Janicak PG, Marder SR, Tandon R, Goldman M (eds). *Schizophrenia: Recent Advances in Diagnosis and Treatment*. New York, New York: Springer; 2014.
- Kane JM, Eerdeken M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *Am J Psychiatry*. 2003;160(6):1125–1132.
- Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2014;75(11):1254–1260.
- Kepinska AP, Iyegbe CO, Vernon AC, et al. Schizophrenia and influenza at the centenary of the 1918–1919 Spanish influenza pandemic: mechanisms of psychosis risk. *Front Psychiatry*. 2020;11:72.
- Kisely S, Warren N, McMahon L, et al. Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis. *BMJ*. 2020;369:m1642.
- Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. *CNS Spectr*. 2019;24(S1):38–69.
- Laffont CM, Gomeni R, Zheng B, et al. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. *J Clin Pharmacol*. 2015;55(1):93–103.
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(2 Suppl):1–56.
- Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. *J Clin Psychiatry*. 1996;57 Suppl 11:68–71.

- Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. *Neuropsychopharmacology*. 1997;17(4):205–229.
- Mahgerefteh S. Treatment challenges in schizophrenia: a multifaceted approach to relapse prevention. *Psychiatric Times*. April 1, 2006. Psychiatric Times website. <https://www.psychiatrictimes.com/view/treatment-challenges-schizophrenia-multifaceted-approach-relapse-prevention>. Accessed July 2020.
- Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *J Clin Psychiatry*. 2015;76(8):1085–1090.
- Miller B. Schizophrenia's lethal infection. *Psychiatric Times*. September 28, 2016. Psychiatric Times website. <https://www.psychiatrictimes.com/view/schizophrenias-lethal-infection>. Accessed July 2020.
- Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. *J Clin Psychopharmacol*. 2016;36(1):18–26.
- National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Updated March 1, 2014. NICE website. <https://www.nice.org.uk/guidance/cg178>. Accessed July 2020.
- Patel MX, Haddad PM, Chaudhry IB, et al. Psychiatrists' use, knowledge, and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. *J Psychopharmacol*. 2010;24(10):1473–1482.
- Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry*. 1999;56(3):241–247.
- Sajatovic M, Ross R, Legacy SN, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics—expert consensus survey part 1. *Neuropsychiatr Dis Treat*. 2018;14:1463–1474.
- van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. *Neuropsychopharmacology*. 2007;32(10):2057–2066.
- Weiden PJ, Claxton A, Kunovac J, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control ALPINE study. *J Clin Psychiatry*. 2020;81(3):19m13207.